CN115304505B - 烯烃羰基化合成酰胺的方法 - Google Patents

烯烃羰基化合成酰胺的方法 Download PDF

Info

Publication number
CN115304505B
CN115304505B CN202110497426.2A CN202110497426A CN115304505B CN 115304505 B CN115304505 B CN 115304505B CN 202110497426 A CN202110497426 A CN 202110497426A CN 115304505 B CN115304505 B CN 115304505B
Authority
CN
China
Prior art keywords
substituted
mmol
amide
aryl
palladium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110497426.2A
Other languages
English (en)
Other versions
CN115304505A (zh
Inventor
关正辉
杨会议
任智卉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NORTHWEST UNIVERSITY
Original Assignee
NORTHWEST UNIVERSITY
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NORTHWEST UNIVERSITY filed Critical NORTHWEST UNIVERSITY
Priority to CN202110497426.2A priority Critical patent/CN115304505B/zh
Publication of CN115304505A publication Critical patent/CN115304505A/zh
Application granted granted Critical
Publication of CN115304505B publication Critical patent/CN115304505B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/10Preparation of carboxylic acid amides from compounds not provided for in groups C07C231/02 - C07C231/08
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00Preparation of carboxylic acid nitriles
    • C07C253/30Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00Preparation of sulfones; Preparation of sulfoxides
    • C07C315/04Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/34Oxygen atoms in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C07D311/723,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F17/00Metallocenes
    • C07F17/02Metallocenes of metals of Groups 8, 9 or 10 of the Periodic System
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00Systems containing at least three condensed rings
    • C07C2603/02Ortho- or ortho- and peri-condensed systems
    • C07C2603/04Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/20Acenaphthenes; Hydrogenated acenaphthenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

本发明公开了一种烯烃羰基化合成酰胺的方法,其以烯烃、一氧化碳与胺在钯催化剂、配体和添加剂的作用下合成酰胺。本发明方法在烯烃羰基化合成酰胺领域表现出优异的特性,反应条件温和,产率高、支链选择性高,可以高效合成具有重要价值的酰胺化合物,实现了环酰菌胺、庚酰草胺等重要酰胺类农药或医药的一步法合成。

Description

烯烃羰基化合成酰胺的方法
技术领域
本发明涉及一类烯烃羰基化反应合成酰胺的方法,属于有机合成技术领域。
背景技术
烯烃与一氧化碳的氢酰胺化反应是合成酰胺化合物最直接、高效的方法之一。在过去的十几年中,烯烃与一氧化碳的氢酰胺化反应取得了重要的进展,钯催化芳基乙烯与一氧化碳和芳胺的氢酰胺化反应已经被用于3-芳基丙酰胺的合成,铑催化烯烃与一氧化碳和脂肪胺的氢酰胺化反应已经被用于脂肪取代基酰胺的合成,钯催化芳基乙烯与一氧化碳和芳胺的氢酰胺化反应已经被用于2-芳基丙酰胺的不对称合成。
Figure 561817DEST_PATH_IMAGE001
由于该类反应过程十分复杂且受底物空间位阻的影响非常明显,烯烃的氢酰胺化反应通常得到线性选择性的酰胺产物,对于工业生产中具有广泛和重要用途的支链型产物却不易获得,目前支链选择性氢酰胺化反应仅限于单取代烯烃和顺式内烯烃。更加常见的反式内烯烃、1,1-二取代烯烃和1,1,2-三取代烯烃在支链选择性氢酰胺化反应中均未表现出活性,这些烯烃的支链选择性氢酰胺化是该领域悬而未决的重要难题之一。
发明内容
本发明的目的是提供一类多取代烯烃的支链选择性氢酰胺化方法,使用本发明的方法可以高效地实现烯烃的支链选择性氢酰胺化反应,特别是对于反式内烯烃、1,1-二取代烯烃和1,1,2-三取代烯烃表现出优异的反应活性和选择性,为环酰菌胺、庚酰草胺等酰胺类农药、医药和精细化工中间体的合成提供新方法。
本发明实现过程如下:
一种烯烃羰基化合成酰胺的方法,其合成路线如下:
Figure 256104DEST_PATH_IMAGE002
R1、R2、R3独立地选自氢、C1-C16的烷基或取代烷基、C2-C40的烷基氧酰基或取代烷基氧酰基、C2-C16的烷基酰基或取代烷基酰基、C3-C12的取代烯基、C6~C20的芳基或取代的芳基、C3~C30的杂芳基或取代的杂芳基、C10~C20的二茂铁基或取代的二茂铁基、氰基;
所述的杂芳基为氮杂芳基、氧杂芳基、硫杂芳基;
所述取代烷基、取代烷氧酰基、取代烷基酰基、取代烯基、取代芳基、取代杂芳基和取代二茂铁基中的取代基为C1~C8的烷基、C1~C6的卤代烷基、C1~C6的烷氧基、C2~C6的酰氧基、C1~C6的酰氨基、C1~C6的烷基氨基、C4~C12的环烷基氨基、C2~C8的酯基、卤素基、硝基、氰基、C1~C7的磺酰基、C6~C18的芳基、C5~C36的饱和或不饱和的环烷基;
或R1与R2、R2与R3形成五元到十六元环;
R4选自C6~C24的芳基或取代芳基,所述取代芳基中的取代基为C1~C12的烷基、C1~C6的烷氧基、C1~C6的烷基氨基、C2~C12的酯基、卤素基、硝基、氰基、C1~C7的磺酰基、C2~C8酰基、C1~C12的卤代烷基、C6~C18的芳基;
R5选自氢、C1~C13的烷基或取代烷基,所述取代烷基中的取代基为C7~C12的苄基、C2~C12的酯基、C1~C12的卤代烷基;
所述的配体选自:
Figure 783031DEST_PATH_IMAGE003
所述的添加剂选自盐酸、硫酸、氢溴酸、氢碘酸、三氟乙酸、对甲苯磺酸、甲磺酸、特戊酸、溴化锂、氯化锂、三氯化铝、三氯化铁。
所述C5~C36的饱和或不饱和的环烷基为饱和或不饱和的环烷基,或C1~C8的烷基或C2~C8的烯基取代的饱和或不饱和的环烷基。
一种优选的方案,R1、R2、R3均不为氢。
另一种优选的方案,R1、R2、R3之一为氢。
还有一种优选的方案,R1不为氢,R2、R3均为氢。
上述烯烃羰基化合成酰胺的反应中,所述的钯催化剂选自Pd2(dba)3、Pd(dba)2、Pd2(C3H5)2Cl2、Pd(CH3CN)2Cl2、Pd(CH3CN)4(BF4)2、Pd(CH3CN)4(CF3SO3)2、Pd(acac)2、Pd(PPh3)4、Pd(PPh3)2Cl2、Pd(P(2-MeOPh)3)2Cl2、氯化钯(π-肉桂基)二聚物、醋酸钯、三氟乙酸钯、氢氧化钯、氯化钯、溴化钯、碘化钯。
上述烯烃羰基化合成酰胺的反应中,所述配体为钯催化剂的0~4倍摩尔量,配体与催化剂共同使用,或先与钯盐配合后再使用。
上述烯烃羰基化合成酰胺的反应中,所述添加剂的加入量为化合物(II)的0.1~3倍摩尔量,添加剂与化合物(II)共同使用,或先与化合物(II)成盐后再使用。
上述烯烃羰基化合成酰胺的反应中,所述的一氧化碳压力为20~80个大气压。
上述烯烃羰基化合成酰胺的反应在有机溶剂中进行,所述的有机溶剂选自四氢呋喃、2-甲基四氢呋喃、1,4-二氧六环、苯甲醚、乙二醇二甲醚、甲基叔丁基醚、甲苯、二氯甲烷、氯仿、1,2-二氯乙烷、丙酮。
上述烯烃羰基化合成酰胺的反应温度为40~140 oC。
本发明的优点:该方法在烯烃羰基化合成酰胺领域表现出优异的特性,反应条件温和,产率高、支链选择性高,可以高效合成具有重要价值的酰胺化合物,实现了环酰菌胺、庚酰草胺等重要酰胺类农药或医药的一步法合成。
具体实施方式
以下通过实例对上述本发明的内容作进一步的详细说明,但本发明不局限于列举的实例。下列实例中未注明具体条件的实验方法,按照常规方法和条件实施。
本发明的方法在反式-1,2-二取代烯烃羰基化生成酰胺中的应用:
实施例1:向2.0毫升玻璃瓶中加入反式二苯乙烯(0.2毫摩尔,1.0当量),苯胺盐酸盐(0.2毫摩尔,1.0当量),Pd(PPh3)2Cl2(0.006毫摩尔,3.0 mol%)和四氢呋喃(1.0毫升)。将玻璃瓶放入高压釜中,用一氧化碳置换釜中空气后加压至40个大气压。将釜置于110 oC下搅拌反应20小时。反应完成后将釜冷却至室温,保持通风良好缓慢排出一氧化碳。柱色谱分离粗产物得到目标酰胺;
Figure 939599DEST_PATH_IMAGE004
白色固体,产率71%, 1H NMR (400 MHz, CDCl3) δ 7.35-7.10 (m, 15H), 7.03(t, J = 7.4 Hz, 1H), 3.74 (t, J = 7.4 Hz, 1H), 3.61 (dd, J = 13.6, 7.6 Hz,1H), 3.04 (dd, J = 13.6, 7.2 Hz, 1H); 高分辨质谱(ESI电离源),m/z C21H19NNaO [M+Na]+的理论值:324.1358, 实测值:324.1366。
实施例2:向2.0毫升玻璃瓶中加入反式二茂铁丙烯(0.3毫摩尔,1.0当量),苯胺(0.3毫摩尔,1.0当量),对甲苯磺酸(0.15毫摩尔,0.5当量),Pd(acac)2(0.006毫摩尔,2.0mol%),PPh3(0.012毫摩尔,4.0 mol%)和四氢呋喃(1.0毫升)。将玻璃瓶放入高压釜中,用一氧化碳置换釜中空气后加压至40个大气压。将釜置于110 oC下搅拌反应12小时。反应完成后将釜冷却至室温,保持通风良好缓慢排出一氧化碳。柱色谱分离粗产物得到目标酰胺;
Figure 334809DEST_PATH_IMAGE005
白色固体,产率76%, 1H NMR (400 MHz, CDCl3) δ 7.94 (s, 1H), 7.54 (d, J =7.6 Hz, 2H), 7.27 (t, J = 7.8 Hz, 2H), 7.07 (t, J = 7.2 Hz, 1H), 4.31 (s,1H), 4.18-4.07 (m, 8H), 3.19 (q, J = 9.2, 4.8 Hz, 1H), 2.05-1.94 (m, 1H),1.93-1.82 (m, 1H), 1.02 (t, J = 7.4 Hz, 3H); 高分辨质谱(ESI电离源),m/zC20H21FeNNaO [M+Na]+的理论值:370.0864, 实测值:370.0862。
实施例3:向5.0毫升玻璃瓶中加入反式-4-辛烯(0.6毫摩尔,1.2当量),苯胺盐酸盐(0.5毫摩尔,1.0当量),Pd(PPh3)4(0.005毫摩尔,1.0 mol%)和乙二醇二甲醚(2.5毫升)。将玻璃瓶放入高压釜中,用一氧化碳置换釜中空气后加压至40个大气压。将釜置于100 oC下搅拌反应36小时。反应完成后将釜冷却至室温,保持通风良好缓慢排出一氧化碳。柱色谱分离粗产物得到目标酰胺;
Figure 24547DEST_PATH_IMAGE006
白色固体,产率97%, 1H NMR (400 MHz, CDCl3) δ 8.04 (s, 1H), 7.57 (d, J =8.0 Hz, 2H), 7.26 (t, J = 7.8 Hz, 2H), 7.07 (t, J = 7.4 Hz, 1H), 2.26-2.19(m, 1H), 1.73-1.65 (m, 2H), 1.49-1.30 (m, 8H), 0.91-0.67 (m, 6H). 高分辨质谱(ESI电离源),m/z C15H23NNaO [M+Na]+的理论值:256.1671, 实测值:256.1681。
实施例4:向2.0毫升玻璃瓶中加入反式-邻氰基苯基-丙烯(0.24毫摩尔,1.2当量),苯胺(0.2毫摩尔,1.0当量),三氟乙酸(0.2毫摩尔,1.0当量),Pd2(C3H5)2Cl2(0.003毫摩尔,1.5 mol%),2-双环己基膦-2',6'-二甲氧基联苯(0.012毫摩尔,6.0 mol%)和1,4-二氧六环(1.5毫升)。将玻璃瓶放入高压釜中,用一氧化碳置换釜中空气后加压至40个大气压。将釜置于110 oC下搅拌反应15小时。反应完成后将釜冷却至室温,保持通风良好缓慢排出一氧化碳。柱色谱分离粗产物得到目标酰胺;
Figure 112589DEST_PATH_IMAGE007
白色固体,产率96%, 1H NMR (400 MHz, CDCl3) δ 8.06 (s, 1H), 7.80 (d, J =8.0 Hz, 1H), 7.64-7.54 (m, 4H), 7.37-7.33 (m, 1H), 7.30-7.25 (m, 2H), 7.08(t, J = 7.4 Hz, 1H), 3.95-3.91 (t, 7.4 Hz, 1H), 2.35-2.24 (m, 1H), 1.92-1.84(m, 1H), 1.01 (t, J = 7.2 Hz, 3H); 高分辨质谱(ESI电离源),m/z C17H16N2NaO [M+Na]+的理论值:287.1154, 实测值:287.1171。
实施例5:向2.0毫升玻璃瓶中加入反式-苯基丙烯(0.24毫摩尔,1.2当量),邻苯基苯胺(0.2毫摩尔,1.0当量),盐酸(0.4毫摩尔,2.0当量),Pd(PPh3)4(0.006毫摩尔,3.0mol%)和丙酮(1.0毫升)。将玻璃瓶放入高压釜中,用一氧化碳置换釜中空气后加压至40个大气压。将釜置于110 oC下搅拌反应8小时。反应完成后将釜冷却至室温,保持通风良好缓慢排出一氧化碳。柱色谱分离粗产物得到目标酰胺;
Figure 487944DEST_PATH_IMAGE008
白色固体,产率96%, 1H NMR (400 MHz, CDCl3) δ 8.32 (d, J = 8.0 Hz, 1H),7.34-7.21 (m, 7H), 7.17-7.03 (m, 7H), 3.20 (t, J = 7.6 Hz, 1H), 2.25-2.14 (m,1H), 1.83-1.69 (m, 2H), 0.84 (t, J = 7.6 Hz, 3H); 13C NMR (400 MHz, CDCl3) δ171.5, 139.0, 137.7, 134.9, 132.0, 130.0, 129.1, 129.0, 128.3, 128.0, 127.7,127.4, 124.1, 121.1, 56.2, 25.9, 12.3。
实施例6:向2.0毫升玻璃瓶中加入 (1E,3E)-1-基苯-1,3-二戊烯(0.24毫摩尔,1.2当量),苯胺盐酸盐(0.2毫摩尔,1.0当量),PdCl2(0.006毫摩尔,3.0 mol%),2-二苯基膦-2'-甲氧基-1,1'-联萘(0.012毫摩尔,6 mol%)和乙二醇二甲醚(1.0毫升)。将玻璃瓶放入高压釜中,用一氧化碳置换釜中空气后加压至45个大气压。将釜置于110 oC下搅拌反应20小时。反应完成后将釜冷却至室温,保持通风良好缓慢排出一氧化碳。柱色谱分离粗产物得到目标酰胺;
Figure 827790DEST_PATH_IMAGE009
白色固体,产率68%, 1H NMR (400 MHz, CDCl3) δ 7.52 (d, J = 8.0 Hz, 2H),7.42-7.40 (m, 2H), 7.35-7.31 (m, 6H), 7.10 (t, J = 7.6 Hz, 1H), 6.59 (d, J =15.6 Hz, 1H), 6.29 (dd, J = 15.6, 8.8 Hz, 1H), 2.10 (m, 1H), 1.77-1.70 (m,1H), 1.0 (t, J = 7.2 Hz, 3H)。
实施例7:与实施例1-6合成方法类似,改变底物可得到不同的酰胺产物。具体底物类型及产率数据见表1,但底物范围不局限于表内,
Figure 231089DEST_PATH_IMAGE010
表1 反式-1,2-二取代烯烃与胺的羰基化反应数据
Figure 866863DEST_PATH_IMAGE011
Figure 230980DEST_PATH_IMAGE012
Figure 967992DEST_PATH_IMAGE013
实施例8:本实施例与实施例1的不同之处仅在于:将苯胺盐酸盐(0.2毫摩尔)改为苯胺(0.2毫摩尔)后,在无盐酸条件下反应,酰胺产率小于10 %。
实施例9:本实施例与实施例1的不同之处仅在于:将四氢呋喃(1.0毫升)改为N-甲基吡咯烷酮(1.0毫升),酰胺产率小于5 %。
实施例10:本实施例与实施例1的不同之处仅在于:将Pd(PPh3)2Cl2(0.006毫摩尔,3.0 mol%)改为Pd( t Bu3P)2(0.006毫摩尔,3 mol%),没有酰胺生成。
实施例11:本实施例与实施例1的不同之处仅在于:将Pd(PPh3)2Cl2(0.006毫摩尔,3.0 mol%)改为Co/C(30.0mg),没有酰胺生成。
实施例12:本实施例与实施例1的不同之处仅在于:将Pd(PPh3)2Cl2(0.006毫摩尔,3.0 mol%)改为RhCl3 .3H2O(0.006毫摩尔,3.0 mol%),没有酰胺生成。
实施例13:本实施例与实施例1的不同之处仅在于:将苯胺盐酸盐(0.2毫摩尔)改为苯胺(0.2毫摩尔),B(OH)3(0.02毫摩尔,10.0 mol%)和5-CISA(0.04毫摩尔,20.0mol%),没有酰胺生成。
实施例14:本实施例与实施例2的不同之处仅在于:将PPh3(0.012毫摩尔,4.0mol%)替换为1,3,5,7-四甲基-6-苯基-2,4,8-三氧杂-6-磷酰金刚烷(0.012毫摩尔,4mol%)时,没有酰胺生成。
实施例15:本实施例与实施例2的不同之处仅在于:将PPh3(0.012毫摩尔,4.0mol%)替换为2-(二苯基膦)-1-(2-甲氧基苯基)吡咯(0.012毫摩尔,4 mol%)时,没有酰胺生成。
实施例16:本实施例与实施例5的不同之处仅在于:将盐酸(0.4毫摩尔)替换为NH4Cl(0.4毫摩尔)或者NH2OH.HCl(0.4毫摩尔)时,没有酰胺生成。
本发明的方法在1,1-二取代烯烃羰基化生成酰胺中的应用:
实施例17:向2.0毫升玻璃瓶中加入对甲磺酰基苯基异丙烯(0.24毫摩尔,1.2当量),苯胺盐酸盐(0.2毫摩尔,1.0当量),Pd(PPh3)2Cl2(0.006毫摩尔,3.0 mol%)和四氢呋喃(1.0毫升)。将玻璃瓶放入高压釜中,用一氧化碳置换釜中空气后加压至50个大气压。将釜置于110 oC下搅拌反应20小时。反应完成后将釜冷却至室温,保持通风良好缓慢排出一氧化碳。柱色谱分离粗产物得到目标酰胺;
Figure 130857DEST_PATH_IMAGE014
白色固体,产率93%, 1H NMR (400 MHz, d 6-DMSO) δ 9.24 (s, 1H), 7.93 (d, J= 8.4 Hz, 2H), 7.65-7.60 (m, 4H), 7.28 (t, J = 7.8 Hz, 2H), 7.04 (t, J = 7.4Hz, 1H), 3.21 (s, 3H), 1.61 (s, 6H); 13C NMR (101 MHz, d 6-DMSO) δ 173.9,151.7, 139.1, 138.9, 128.5, 127.1, 127.0, 123.5, 120.4, 47.8, 43.6, 26.6。
实施例18:用与实施例17相同的方法,改变底物可以得到如下产物,
Figure 436068DEST_PATH_IMAGE015
白色固体,产率83%, 1H NMR (400 MHz, CDCl3) δ 7.38 (d, J = 8.0 Hz, 2H),7.26 (t, J = 7.6 Hz, 2H), 7.05 (t, J = 7.4 Hz, 1H), 6.91-6.89 (m, 3H), 6.83-6.81 (m, 1H), 5.97 (s, 2H), 1.62 (s, 6H); 13C NMR (101 MHz, CDCl3) δ 175.6,148.3, 146.9, 138.6, 138.1, 129.0, 124.2, 119.7, 119.6, 108.5, 107.4, 101.4,47.9, 27.3. 高分辨质谱(ESI电离源),m/z C17H17NNaO3 [M+Na]+的理论值:306.1100, 实测值:306.1114。
实施例19:向2.0毫升玻璃瓶中加入2-异丙烯基萘(0.24毫摩尔,1.2当量),苯胺(0.2毫摩尔,1.0当量),甲酸(0.2毫摩尔,1.0当量),PdCl2(0.006毫摩尔,3.0 mol%),dppf(0.006毫摩尔,3.0 mol%)和2-甲基四氢呋喃(1.2毫升)。将玻璃瓶放入高压釜中,用一氧化碳置换釜中空气后加压至40个大气压。将釜置于110 oC下搅拌反应24小时。反应完成后将釜冷却至室温,保持通风良好缓慢排出一氧化碳。柱色谱分离粗产物得到酰胺;
Figure 412114DEST_PATH_IMAGE016
白色固体,产率79%, 1H NMR (400 MHz, CDCl3) δ 7.69-7.82 (m, 4H), 7.52-7.45 (m, 3H),7.32 (d, J = 8.0 Hz, 2H) 7.20 (t, J = 7.2 Hz, 2H), 7.01 (t, J =7.2Hz, 2H), 6.86 (s, 1H), 1.74 (s, 6H); 13C NMR (101 MHz, CDCl3) δ 175.5,142.1, 138.0, 133.4, 132.8, 128.9, 128.2, 127.7, 126.7, 126.4, 125.4, 124.6,124.2, 119.8, 48.4, 27.1。
实施例20:向2.0毫升玻璃瓶中加入2-异丙烯基噻吩(0.24毫摩尔,1.2当量),苯胺(0.2毫摩尔,1.0当量),三氯化铝(0.2毫摩尔,1.0当量),PdCl2(0.006毫摩尔,3.0 mol%),PPh3(0.012毫摩尔,6.0 mol%)和四氢呋喃(1.2毫升)。将玻璃瓶放入高压釜中,用一氧化碳置换釜中空气后加压至40个大气压。将釜置于110 oC下搅拌反应24小时。反应完成后将釜冷却至室温,保持通风良好缓慢排出一氧化碳。柱色谱分离粗产物得到酰胺;
Figure 306211DEST_PATH_IMAGE017
白色固体,产率48%, 1H NMR (400 MHz, CDCl3) δ 7.36 (d, J = 8.0 Hz, 2H),7.33 (d, J = 4.8 Hz, 1H), 7.28-7.25 (m, 2H), 7.18 (s, 1H), 7.10 (d, J = 2.8Hz, 1H), 7.08-7.05 (m, 2H), 1.75 (s, 6H); 13C NMR (101 MHz, CDCl3) δ 174.2,149.6, 137.9, 129.0, 127.5, 125.5, 125.1, 124.4, 119.8, 46.4, 28.3。
实施例21:向2.0毫升玻璃瓶中加入1-亚甲基茚烷(0.24毫摩尔,1.2当量),苯胺盐酸盐(0.2毫摩尔,1.0当量),Pd(PPh3)4(0.006毫摩尔,3.0 mol%)和四氢呋喃(1.2毫升)。将玻璃瓶放入高压釜中,用一氧化碳置换釜中空气后加压至50个大气压。将釜置于115 oC下搅拌反应30小时。反应完成后将釜冷却至室温,保持通风良好缓慢排出一氧化碳。柱色谱分离粗产物得到目标酰胺;
Figure 949681DEST_PATH_IMAGE018
白色固体,产率75%, 1H NMR (600 MHz, CDCl3) δ 7.36-7.31 (m, 6H), 7.26-7.24 (m, 2H), 7.06 (t, J = 6.0 Hz, 2H), 3.03-2.96 (m, 2H), 2.73-2.70 (m, 1H),2.14-2.09 (m, 1H), 1.65 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 174.9, 145.7,144.9, 137.8, 129.0, 128.4, 127.5, 125.7, 124.3, 123.7, 119.7, 56.7, 40.2,30.6, 24.5。
实施例22:向2.0毫升玻璃瓶中加入2-苯基戊烯(0.24毫摩尔,1.2当量),苯胺盐酸盐(0.2毫摩尔,1.0当量),Pd(PPh3)2Cl2(0.006毫摩尔,3.0 mol%)和四氢呋喃(0.6毫升)。将玻璃瓶放入高压釜中,用一氧化碳置换釜中空气后加压至70个大气压。将釜置于120 oC下搅拌反应100小时。反应完成后将釜冷却至室温,保持通风良好缓慢排出一氧化碳。柱色谱分离粗产物得到目标酰胺;
Figure 160214DEST_PATH_IMAGE019
白色固体,产率51%, 1H NMR (400 MHz, CDCl3) δ 7.41-7.34 (m, 5H), 7.32-7.29 (m, 1H), 7.28-7.24 (m, 3H), 7.07-7.03 (m, 1H), 6.79 (s, 1H), 2.11-1.98(m, 2H), 1.62 (s, 3H), 1.32-1.26 (m, 1H), 1.20-1.12 (m, 1H), 0.92 (t, J = 6.8Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 175.4, 143.9, 138.1, 129.1, 129.0, 127.4,127.1, 124.2, 119.8, 51.8, 41.3, 24.1, 17.9, 14.8。
实施例23:向5.0毫升玻璃瓶中加入甲基丙烯酸甲酯(1.2毫摩尔,1.2当量),苯胺盐酸盐(1.0毫摩尔,1.0当量),Pd(CH3CN)4(BF4)2(0.005毫摩尔,0.5 mol%)2-(二苯基膦基)-联苯(0.01毫摩尔,1.0 mol%)和四氢呋喃(3.0毫升)。将玻璃瓶放入高压釜中,用一氧化碳置换釜中空气后加压至40个大气压。将釜置于110 oC下搅拌反应40小时。反应完成后将釜冷却至室温,保持通风良好缓慢排出一氧化碳。柱色谱分离粗产物得到目标酰胺;
Figure 997458DEST_PATH_IMAGE020
白色固体,产率86%, 1H NMR (400 MHz, CDCl3) δ 8.55 (s, 1H), 7.53 (d, J =7.6 Hz, 2H), 7.32 (t, J = 7.6 Hz, 2H), 7.11 (t, J = 7.2 Hz, 1H), 3.79 (s,3H), 1.56 (s, 6H); 13C NMR (101 MHz, CDCl3) δ 176.1, 169.7, 137.9, 129.1,124.5, 120.1, 53.1, 50.6, 24.0。
实施例24:与实施例23方案相同,改变原料可以得到如下产物,
Figure 76272DEST_PATH_IMAGE021
白色固体,产率65%, 1H NMR (400 MHz, CDCl3) δ 8.65 (s, 1H), 7.54-7.51(m, 2H), 7.34-7.29 (m, 2H), 7.12-7.08 (m, 1H), 5.39 (d, J = 4.4 Hz, 1H),4.74-4.66 (m, 1H), 2.35 (d, J = 7.2 Hz, 2H), 2.03-1.95 (m, 2H), 1.90-1.82 (m,3H), 1.69-1.62 (m, 2H), 1.59-1.57 (m, 1H), 1.54 (s, 6H), 1.51-1.43 (m, 4H),1.37-1.30 (m, 2H), 1.28-1.19 (m, 3H), 1.20-1.10 (m, 6H), 1.02 (s, 3H), 0.96(d, J = 6.0 Hz, 1H), 0.92 (d, J = 6.4 Hz, 3H), 0.86-0.81 (m, 10H), 0.68 (s,3H); 高分辨质谱(ESI电离源),m/z C39H59NNaO3 [M+Na]+的理论值:626.4543, 实测值:626.4513。
Figure 715195DEST_PATH_IMAGE022
白色固体,产率89%, 1H NMR (600 MHz, CDCl3) δ 8.80 (s, 1H), 7.54 (d, J =8.4 Hz, 2H), 7.32 (t, J = 7.5 Hz, 2H), 7.11 (t, J = 7.2 Hz, 1H), 2.59 (t, J =6.6 Hz, 2H), 2.09 (s, 3H), 2.00 (s, 3H), 1.95 (s, 3H), 1.78 (s, 6H), 1.58-1.50 (m, 3H), 1.37 (s, 3H), 1.26-1.22 (m, 11H), 1.14-1.06 (m, 7H), 0.87-0.84(m, 14H); 高分辨质谱(ESI电离源),m/z C40H61NNaO4 [M+Na]+的理论值:642.4492, 实测值:642.4463。
实施例25:向2.0毫升玻璃瓶中加入对氯苯基异丙烯(0.24毫摩尔,1.2当量),2-溴-5-氯苯胺(0.2毫摩尔,1.0当量),盐酸(0.2毫摩尔,1.0当量),PdCl2(0.006毫摩尔,3.0mol%),P(2-MeOPh)3(0.012毫摩尔,6.0 mol%)和四氢呋喃(1.0毫升)。将玻璃瓶放入高压釜中,用一氧化碳置换釜中空气后加压至45个大气压。将釜置于110 oC下搅拌反应24小时。反应完成后将釜冷却至室温,保持通风良好缓慢排出一氧化碳。柱色谱分离粗产物得到目标酰胺;
Figure 598094DEST_PATH_IMAGE023
白色固体,产率62%,1H NMR (400 MHz, CDCl3) δ 8.43 (d, J = 2.4 Hz, 1H),7.47 (s, 1H), 7.42-7.37 (m, 4H), 7.33 (d, J = 8.4 Hz, 1H), 6.90 (dd, J = 8.6,2.4 Hz, 1H), 1.68 (s, 6H); 13C NMR (101 MHz, CDCl3) δ 175.2, 142.4, 136.5,134.3, 133.7, 132.7, 129.3, 128.1, 125.0, 121.2, 111.0, 48.2, 26.8。
实施例26:向2.0毫升玻璃瓶中加入亚甲基环己烷(0.24毫摩尔,1.2当量),2,3-二氯-4-氨基苯酚盐酸盐(0.2毫摩尔,1.0当量),Pd(PPh3)2Cl2(0.006毫摩尔,3.0 mol%)和四氢呋喃(0.6毫升)。将玻璃瓶放入高压釜中,用一氧化碳置换釜中空气后加压至40个大气压。将釜置于110 oC下搅拌反应24小时。反应完成后将釜冷却至室温,保持通风良好缓慢排出一氧化碳。柱色谱分离粗产物得到农药环酰菌胺;
Figure 814312DEST_PATH_IMAGE024
白色固体,产率69%, 1H NMR (400 MHz, CDCl3) δ 8.05 (d, J = 9.2 Hz, 1H),7.75 (s, 1H), 6.94 (d, J = 9.2 Hz, 1H), 5.93 (s, 1H), 2.06-2.02 (m, 2H),1.65-1.60 (m, 2H), 1.57-1.52 (m, 4H), 1.46-1.37 (m, 2H), 1.29 (s, 3H); 13C NMR(151 MHz, CDCl3) δ 176.5, 149.4, 128.9, 123.3, 122.1, 119.1, 114.8, 44.2,35.8,26.7, 25.8, 23.0. 高分辨质谱(ESI电离源),m/z C14H17Cl2NNaO2 [M+Na]+的理论值:324.0528, 实测值:324.0529。
实施例27:向2.0毫升玻璃瓶中加入2-甲基戊烯(0.24毫摩尔,1.2当量),苯胺盐酸盐(0.2毫摩尔,1.0当量),Pd(P(2-MeOPh)3)2Cl2(0.006毫摩尔,3.0 mol%)和四氢呋喃(1.2毫升)。将玻璃瓶放入高压釜中,用一氧化碳置换釜中空气后加压至40个大气压。将釜置于110 oC下搅拌反应24小时。反应完成后将釜冷却至室温,保持通风良好缓慢排出一氧化碳。柱色谱分离粗产物得到农药庚酰草胺;
Figure 572183DEST_PATH_IMAGE025
白色固体,产率 71%, b/l = 95:5, 1H NMR (400 MHz, CDCl3) δ 7.47-7.43 (m,3H), 7.27-7.23 (m, 2H), 1.58-1.54 (m, 2H), 1.35-1.26 (m, 8H), 0.90 (t, J =7.2 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 176.3, 136.7, 129.2, 128.9, 121.6,43.9, 43.2, 25.5, 18.2, 14.7. 高分辨质谱(ESI电离源),m/z C13H18ClNNaO [M+Na]+的理论值:262.0969, 实测值:262.0969。
实施例28:向5.0毫升玻璃瓶中加入2-异丙烯基苯胺(0.5毫摩尔),盐酸(0.3毫摩尔),Pd(PPh3)2Cl2(0.005毫摩尔,1.0 mol%)和四氢呋喃(2.0毫升)。将玻璃瓶放入高压釜中,用一氧化碳置换釜中空气后加压至40个大气压。将釜置于100 oC下搅拌反应36小时。反应完成后将釜冷却至室温,保持通风良好缓慢排出一氧化碳。柱色谱分离粗产物得到目标酰胺;
Figure 924667DEST_PATH_IMAGE026
白色固体,产率95%, 1H NMR (400 MHz, CDCl3) δ 8.81 (s, 1H), 7.22-7.21(m, 2H), 7.06-7.02 (m, 1H), 6.96-6.93 (m,1H), 1.41 (s, 6H); 13C NMR (101 MHz,CDCl3) δ 184.3, 140.0, 136.1, 127.8, 122.7, 122.6, 110.0, 44.8, 24.5。
实施例29:向2.0毫升玻璃瓶中加入2-苯丙烯(0.24毫摩尔,1.2当量),4-溴-N-甲基苯胺盐酸盐(0.2毫摩尔,1.0当量),PdCl2(0.006毫摩尔,3.0 mol%),P(2-MeOPh)3(0.012毫摩尔,6.0 mol%)和乙二醇二甲醚(1.5毫升)。将玻璃瓶放入高压釜中,用一氧化碳置换釜中空气后加压至40个大气压。将釜置于110 oC下搅拌反应24小时。反应完成后将釜冷却至室温,保持通风良好缓慢排出一氧化碳。柱色谱分离粗产物得到目标酰胺;
Figure 241117DEST_PATH_IMAGE027
白色固体,产率75%, 1H NMR (600 MHz, d 6-DMSO) δ 7.34-7.22 (m, 5H), 7.09(s, 2H), 6.80 (s, 2H), 2.90 (s, 3H), 1.39 (s, 6H); 13C NMR (151 MHz, d 6-DMSO)δ 174.9, 145.8, 143.5, 131.5, 130.1, 128.6, 126.4, 125.0, 119.5, 47.0, 28.4。
实施例30:与实施例29相同,改变底物可得如下产物;
Figure 554417DEST_PATH_IMAGE028
白色固体,产率52%, 1H NMR (400 MHz, CDCl3) δ 8.33 (d, J = 8.0 Hz, 1H),7.35-7.29 (m, 4H), 7.26-7.20 (m, 3H), 7.11 (d, J = 6.8 Hz, 1H), 7.00 (t, J =7.6 Hz, 1H), 3.37 (t, J = 8.0 Hz, 2H), 2.78 (t, J = 8.0 Hz, 2H), 1.65 (s,6H); 13C NMR (101 MHz, CDCl3) δ 175.0, 145.6, 144.5, 131.2, 129.1, 127.5,126.7, 125.5, 124.4, 123.9, 118.4, 49.0, 48.7, 28.9, 27.8。
实施例31:与实施例17-29合成方法类似,改变底物可得到不同产物。具体底物类型及产率数据见表2, 但底物范围不局限于表内,
Figure 975034DEST_PATH_IMAGE029
Figure 824435DEST_PATH_IMAGE030
Figure 547672DEST_PATH_IMAGE031
Figure 472902DEST_PATH_IMAGE032
实施例32:本实施例与实施例17的不同之处仅在于:将苯胺盐酸盐(0.2毫摩尔)改为苯胺(0.2毫摩尔),产率小于5 %。
实施例33:本实施例与实施例17的不同之处仅在于:将四氢呋喃(1.0毫升)改为N-甲基吡咯烷酮(1.0毫升),没有酰胺生成。
实施例34:本实施例与实施例17的不同之处仅在于:将Pd(PPh3)2Cl2(0.006毫摩尔,3.0 mol%)改为Co/C(30.0mg),没有酰胺生成。
实施例35:本实施例与实施例17的不同之处仅在于:将Pd(PPh3)2Cl2(0.006毫摩尔,3.0 mol%)改为RhCl3 .3H2O(0.006毫摩尔,3.0 mol%),没有酰胺生成。
实施例36:本实施例与实施例17的不同之处仅在于:将把Pd(PPh3)2Cl2(0.006毫摩尔,3.0 mol%)改为Pd( t Bu3P)2(0.006毫摩尔,3 mol%),没有酰胺生成。
实施例37:本实施例与实施例17的不同之处仅在于:将苯胺盐酸盐(0.2毫摩尔)改为苯胺(0.2毫摩尔),B(OH)3(0.02毫摩尔,10.0 mol%)和5-氯水杨酸(0.04毫摩尔,20.0mol%),没有酰胺生成。
实施例38:本实施例与实施例25的不同之处仅在于:将盐酸(0.2毫摩尔)改为B(OH)3(0.2毫摩尔)时,没有酰胺生成。
实施例39:本实施例与实施例25的不同之处仅在于:将盐酸(0.2毫摩尔)改为NH4Cl(0.2毫摩尔)或NH2OH.HCl(0.2毫摩尔)时,没有酰胺生成。
实施例40:本实施例与实施例25的不同之处仅在于:将PPh3(0.012毫摩尔,6.0mol%)替换为1,3,5,7-四甲基-6-苯基-2,4,8-三氧杂-6-磷酰金刚烷(0.012毫摩尔,6mol%)时,没有酰胺生成。
实施例41:本实施例与实施例25的不同之处仅在于:将PPh3(0.006毫摩尔,3.0mol%)替换为2-(二苯基膦)-1-(2-甲氧基苯基)吡咯(0.006毫摩尔,3.0 mol%)时,没有酰胺生成。
本发明的方法在1,1,2-三取代烯烃羰基化生成酰胺中的应用:
实施例42:向2.0毫升玻璃瓶中加入2-(3’,4’-二甲氧基)苯丁烯(0.24毫摩尔,1.2当量),苯胺盐酸盐(0.2毫摩尔,1.0当量),Pd(PPh3)2Cl2(0.006毫摩尔,3.0 mol%)和四氢呋喃(0.5毫升)。将玻璃瓶放入高压釜中,用一氧化碳置换釜中空气后加压至60个大气压。将釜置于120 oC下反应96小时。反应完成后将釜冷却至室温,保持通风良好排出一氧化碳。柱色谱分离粗产物得到目标酰胺;
Figure 71112DEST_PATH_IMAGE033
白色固体,产率67%, 1H NMR (400 MHz, CDCl3) δ 7.36 (d, J = 7.6 Hz, 2H),7.25 (t, J = 7.2 Hz, 2H), 7.04 (t, J = 7.2 Hz, 1H), 6.97 (dd, J = 7.4, 2.0Hz, 1H), 6.92 (s, 1H), 6.89-6.86 (m, 2H), 3.90 (s, 3H), 3.85 (s, 3H), 2.20-2.04 (m, 2H), 1.59 (s, 3H), 0.83 (t, J = 7.6 Hz, 3H); 13C NMR (101 MHz, CDCl3)δ 175.6, 149.2, 148.2, 138.0, 135.8, 128.9, 124.1, 119.6, 119.0, 111.0,110.3, 56.0, 55.9, 51.5, 31.5, 23.3, 8.9。
实施例43:与实施例42相同,仅改变烯烃原料可得到如下酰胺产物,
Figure 273554DEST_PATH_IMAGE034
白色固体,产率51%, 1H NMR (400 MHz, CDCl3)δ 7.51 (d, J = 8.8 Hz, 2H),7.37 (d, J = 8.0 Hz, 2H), 7.29-7.25 (m, 4H), 7.07 (t, J = 7.2 Hz, 1H), 6.78(s, 1H), 2.17-2.00 (m, 2H), 1.58 (s, 3H), 0.84 (t, J = 7.6 Hz, 3H); 13C NMR(101 MHz, CDCl3) δ 174.5, 142.8, 137.9, 132.1, 129.1, 128.9, 124.4, 121.4,119.9, 51.7, 31.7, 23.3, 8.9。
Figure 557905DEST_PATH_IMAGE035
白色固体,产率65%, 1H NMR (400 MHz, CDCl3) δ 7.39-7.36 (m, 2H), 7.31-7.30 (m, 3H), 7.29-7.24 (m, 3H), 7.19 (s, 1H), 7.06 (t, J = 7.2 Hz, 1H),3.04-2.91 (m, 2H), 2.65-2.58 (m, 1H), 2.24-2.17 (m, 1H), 2.12-2.06 (m, 2H),0.91 (t, J = 7.6 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 174.3, 145.6, 144.1,139.0, 129.0, 128.3, 127.2, 125.7, 124.4, 124.3, 119.8, 61.4, 36.7, 30.5,30.0, 9.6。
实施例44:向2.0毫升玻璃瓶中加入当归酸甲酯(0.24毫摩尔,1.2当量),苯胺(0.2毫摩尔,1.0当量),盐酸(0.4毫摩尔,2.0当量),三氟乙酸钯(0.006毫摩尔,3.0 mol%),PPh3(0.012毫摩尔,6.0 mol%)和乙二醇二甲醚(0.6毫升)。将玻璃瓶放入高压釜中,用一氧化碳置换釜中空气后加压至60个大气压。将釜置于120 oC下反应96小时。反应完成后将釜冷却至室温,保持通风良好缓慢排出一氧化碳。柱色谱分离粗产物得到目标酰胺;
Figure 347263DEST_PATH_IMAGE036
白色固体,产率63%,1H NMR (400 MHz, CDCl3) δ 9.18 (s, 1H), 7.57-7.55 (m,2H), 7.33 (t, J = 7.6 Hz, 2H), 7.11 (t J = 7.6 Hz, 1H), 3.80 (s, 3H), 2.15-2.60 (m, 1H), 1.98-1.89 (m, 1H), 1.52 (s, 3H), 0.91 (t, J = 7.2 Hz, 3H); 13CNMR (101 MHz, CDCl3) δ 176.4, 169.3, 137.9, 129.1, 124.4, 120.1, 54.9, 53.0,32.2, 20.6, 9.7。
实施例45:与实施例44相同,仅改变烯烃原料可得如下酰胺产物,
Figure 109682DEST_PATH_IMAGE037
白色固体,产率63%, b/l = 81:19,1H NMR (400 MHz, CDCl3) δ 8.23 (s, 1H),7.53-7.51 (m, 2H), 7.32 (t, J = 7.6 Hz, 2H), 7.10 (t, J = 7.2 Hz, 1H), 3.78(s, 3H), 2.33-2.27 (m, 4H), 1.81-1.67 (m, 4H); 高分辨质谱(ESI电离源),m/zC14H17NNaO3 [M+Na]+的理论值:270.1100,实测值:270.1100。
Figure 166631DEST_PATH_IMAGE038
白色固体,产率55%, 1H NMR (600 MHz, CDCl3) δ 7.54 (d, J = 7.2 Hz, 2H),7.37 (s, 1H), 7.33-7.30 (m, 2H), 7.10 (t, J = 7.2 Hz, 1H), 2.03-2.01 (m, 2H),1.62-1.58 (m, 2H), 1.54-1.47 (m, 3H), 1.45-1.41 (m, 2H), 1.39-1.36 (m, 1H),1.26 (s, 3H); 高分辨质谱(ESI电离源),m/z C14H19NNaO [M+Na]+的理论值:240.1358,实测值:240.1357。
实施例46:与实施例42和44的合成方法类似,改变底物可得到不同酰胺产物。具体底物类型及产率见表3,但底物范围不局限于表内,
Figure 995785DEST_PATH_IMAGE039
Figure 895608DEST_PATH_IMAGE040
实施例47:本实施例与实施例42的不同之处仅在于:将苯胺盐酸盐(0.2毫摩尔)改为苯胺(0.2毫摩尔),没有酰胺生成。
实施例48:本实施例与实施例42的不同之处仅在于:将Pd(PPh3)2Cl2(0.006毫摩尔,3.0 mol%)改为Pd( t Bu3P)2(0.006毫摩尔,3 mol%),没有酰胺生成。
实施例49:本实施例与实施例44的不同之处仅在于:将PPh3(0.006毫摩尔,3.0mol%)替换为2-(二苯基膦)-1-(2-甲氧基苯基)吡咯(0.006毫摩尔,3.0 mol%),没有酰胺生成。
实施例50:本实施例与实施例44的不同之处仅在于:将盐酸(0.4毫摩尔)替换为NH4Cl(0.4毫摩尔)或者NH2OH.HCl(0.4毫摩尔),没有酰胺生成。
本发明的新方法也适用于单取代烯烃、顺式-1,2-二取代烯烃和其他类型烯烃的氢酰胺化:
实施例51:向5.0毫升玻璃瓶中加入4-异丁基苯乙烯(0.6毫摩尔,1.2当量),苯胺盐酸盐(0.5毫摩尔,1.0当量),Pd(PPh3)2Cl2(0.005毫摩尔,1.0 mol%),和四氢呋喃(2.5毫升)。将玻璃瓶放入高压釜中,用一氧化碳置换釜中空气后加压至30个大气压。将釜置于100oC下搅拌反应24小时。反应完成后将釜冷却至室温,保持通风良好缓慢排出一氧化碳。柱色谱分离粗产物得到目标酰胺;
Figure 337084DEST_PATH_IMAGE041
白色固体,产率98%,1H NMR (400 MHz, CDCl3) δ 7.42 (d, J = 8.0 Hz, 2H),7.34 (s, 1H), 7.26-7.22 (m, 4H), 7.13 (d, J = 7.6 Hz, 2H), 7.04 (t, J = 7.6Hz, 1H), 3.69 (q, J = 7.2 Hz, 1H), 2.46 (d, J = 7.2 Hz, 2H), 1.90-1.80 (m,1H), 1.56 (d, J = 7.2 Hz, 3H), 0.90 (d, J = 6.4 Hz, 6H)。
实施例52:与实施例51相同,仅改变底物可得到如下酰胺产物,
Figure 750004DEST_PATH_IMAGE042
白色固体,产率92%, 1H NMR (400 MHz, d 6 -DMSO) δ 10.14 (s, 1H), 7.61 (d,J = 7.6 Hz, 2H), 7.54-7.52 (m, 2H), 7.49-7.44 (m, 3H), 7.40-7.38 (m, 1H),7.33-7.27 (m, 4H), 7.03 (t, J = 7.6 Hz, 1H), 3.91 (q, J = 7.2 Hz, 1H), 1.46(d, J = 7.2 Hz, 3H)。
Figure 376158DEST_PATH_IMAGE043
白色固体,产率95%, 1H NMR (400 MHz, CDCl3) δ 7.84 (s, 1H), 7.80 (d, J =7.6 Hz, 2H), 7.71-7.66 (m, 2H), 7.61 (t, J = 7.2 Hz, 1H), 7.49 (t, J = 7.2Hz, 6H), 7.29 (t, J = 8.8 Hz, 2H), 7.10 (t, J = 7.2 Hz, 1H), 3.80 (q, J = 7.2Hz, 1H), 1.62 (d, J = 6.8 Hz, 3H)。
Figure 638643DEST_PATH_IMAGE044
白色固体,产率97%, 1H NMR (400 MHz, CDCl3) δ 7.90 (s, 1H), 7.44 (d, J =8.0 Hz, 2H), 7.21 (t, J = 22.5, 7.2 Hz, 6H), 7.04 (t, J = 7.3 Hz, 1H), 3.97(t, J = 7.4 Hz, 1H), 3.11-2.97 (m, 1H), 2.94-2.80 (m, 1H), 2.46-2.30 (m, 2H);高分辨质谱(ESI电离源),m/z C16H15NNaO [M+Na]+的理论值:260.1045,实测值:260.1052。
Figure 116767DEST_PATH_IMAGE045
白色固体,产率86%, 1H NMR (400 MHz, DMSO-d 6) δ 10.53 (s, 1H), 7.72-7.67(m, 4H), 7.53-7.46 (m, 3H), 7.39 (d, J = 6.8 Hz, 1H), 7.33 (t, J = 7.8 Hz,2H), 7.07 (t, J = 7.4 Hz, 1H), 4.68 (dd, J = 8.0, 3.2 Hz, 1H), 3.75 (dd, J =17.2, 3.2 Hz, 1H), 3.59 (dd, J = 17.2, 8.0 Hz, 1H), 3.38 (s, 6H); 高分辨质谱(ESI电离源),m/z C19H15NNaO [M+Na]+的理论值:296.1045,实测值:296.1032。
Figure 272942DEST_PATH_IMAGE046
白色固体,产率78% 1H NMR (400 MHz, CDCl3) δ 7.77 (s, 1H), 7.54 (d, J =8.0 Hz, 2H), 7.27 (t, J = 7.6 Hz, 2H), 7.06 (t, J = 7.4 Hz, 1H), 2.67 (t, J =8.1 Hz, 1H), 1.87 (dd, J = 12.4, 5.2 Hz, 4H), 1.73 (dd, J = 11.1, 4.7 Hz,2H), 1.63-1.51 (m, 2H)。
Figure 945362DEST_PATH_IMAGE047
白色固体,产率85%, 1H NMR (400 MHz, CDCl3) δ 7.51 (d, J = 8.0 Hz, 2H),7.43-7.39 (m, 3H), 7.35-7.25 (m, 5H), 7.09 (t, J = 7.2 Hz, 1H), 6.61 (d, J =15.6 Hz, 1H), 6.33 (dd, J = 15.6, 8.2 Hz, 1H), 3.34-3.27 (m, 1H), 1.45 (d, J= 7.2 Hz, 3H)。
实施例53:与实施例51相同,改变底物且增大一氧化碳压力为45个大气压,可得到如下酰胺产物,
Figure 931029DEST_PATH_IMAGE048
白色固体,产率62%, 1H NMR (400 MHz, CDCl3) δ 7.47 (d, J = 7.6 Hz, 2H),7.42 (s, 1H), 7.31-7.23 (m, 4H), 7.05 (t, J = 7.2 Hz, 1H), 6.84 (d, J = 8.8Hz, 2H), 3.78 (s, 3H), 2.97 (d, J = 10.0 Hz, 1H), 2.51-2.42 (m, 1H), 1.09 (d,J = 6.4 Hz, 3H), 0.74 (d, J = 6.8 Hz, 3H)。
实施例54:与实施例51合成方法类似,改变底物可得到不同产物。具体底物类型及产率见表4,但底物范围不局限于表内,
Figure 104522DEST_PATH_IMAGE049
Figure 990569DEST_PATH_IMAGE050
Figure 332427DEST_PATH_IMAGE051
Figure 303925DEST_PATH_IMAGE052
最后有必要在此说明的是:上述实施例只用于对本发明的技术方案作进一步详细地说明,不能理解为对本发明保护范围的限制。本领域技术人员可以理解,根据本发明的上述内容,可对本发明做出一些修改或调整。这些修改或调整也应当在本发明权利要求所限定的范围之内。

Claims (5)

1.烯烃羰基化合成酰胺的方法,其特征在于:
Figure FDA0004246379050000011
R1、R2、R3独立地选自C1-C16的烷基或取代烷基、C2-C40的烷基氧酰基或取代烷基氧酰基、C2-C16的烷基酰基或取代烷基酰基、C3-C12的取代烯基、C6~C20的芳基或取代的芳基、C3~C30的杂芳基或取代的杂芳基、C10~C20的二茂铁基或取代的二茂铁基、氰基,或R1与R2、R2与R3形成五元到十六元环;
或者,
R1、R2独立地选自C1-C16的烷基或取代烷基、C2-C40的烷基氧酰基或取代烷基氧酰基、C2-C16的烷基酰基或取代烷基酰基、C3-C12的取代烯基、C6~C20的芳基或取代的芳基、C3~C30的杂芳基或取代的杂芳基、C10~C20的二茂铁基或取代的二茂铁基、氰基,R3为氢;
所述的杂芳基为氮杂芳基、氧杂芳基、硫杂芳基;
所述取代烷基、取代烷氧酰基、取代烷基酰基、取代烯基、取代芳基、取代杂芳基和取代二茂铁基中的取代基为C1~C8的烷基、C1~C6的卤代烷基、C1~C6的烷氧基、C2~C6的酰氧基、C1~C6的酰氨基、C1~C6的烷基氨基、C4~C12的环烷基氨基、C2~C8的酯基、卤素基、硝基、氰基、C1~C7的磺酰基、C6~C18的芳基、C5~C36的饱和或不饱和的环烷基;
R4选自C6~C24的芳基或取代芳基,所述取代芳基中的取代基为C1~C12的烷基、C1~C6的烷氧基、C1~C6的烷基氨基、C2~C12的酯基、卤素基、硝基、氰基、C1~C7的磺酰基、C2~C8酰基、C1~C12的卤代烷基、C6~C18的芳基;
R5选自氢、C1~C13的烷基或取代烷基,所述取代烷基中的取代基为C7~C12的苄基、C2~C12的酯基、C1~C12的卤代烷基;
所述钯催化剂选自Pd2(dba)3、Pd(dba)2、Pd2(C3H5)2Cl2、Pd(CH3CN)2Cl2、Pd(CH3CN)4(BF4)2、Pd(CH3CN)4(CF3SO3)2、Pd(acac)2、Pd(PPh3)4、Pd(PPh3)2Cl2、Pd(P(2-MeOPh)3)2Cl2、氯化钯(π-肉桂基)二聚物、醋酸钯、三氟乙酸钯、氢氧化钯、氯化钯、溴化钯、碘化钯;
所述的添加剂选自盐酸、硫酸、氢溴酸、氢碘酸、三氟乙酸、对甲苯磺酸、甲磺酸、特戊酸、溴化锂、氯化锂、三氯化铝、三氯化铁;
所述的配体选自:
Figure FDA0004246379050000021
上述反应在有机溶剂中进行,所述的有机溶剂选自四氢呋喃、2-甲基四氢呋喃、1,4-二氧六环、苯甲醚、乙二醇二甲醚、甲基叔丁基醚、甲苯、二氯甲烷、氯仿、1,2-二氯乙烷、丙酮。
2.根据权利要求1所述烯烃羰基化合成酰胺的方法,其特征在于:所述配体与催化剂共同使用,或先与钯盐配合后再使用。
3.根据权利要求1所述烯烃羰基化合成酰胺的方法,其特征在于:所述添加剂与化合物(II)共同使用,或先与化合物(II)成盐后再使用。
4.根据权利要求1所述烯烃羰基化合成酰胺的方法,其特征在于:所述的一氧化碳压力为20~80个大气压。
5.根据权利要求1所述烯烃羰基化合成酰胺的方法,其特征在于:反应温度为40~140℃。
CN202110497426.2A 2021-05-08 2021-05-08 烯烃羰基化合成酰胺的方法 Active CN115304505B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110497426.2A CN115304505B (zh) 2021-05-08 2021-05-08 烯烃羰基化合成酰胺的方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110497426.2A CN115304505B (zh) 2021-05-08 2021-05-08 烯烃羰基化合成酰胺的方法

Publications (2)

Publication Number Publication Date
CN115304505A CN115304505A (zh) 2022-11-08
CN115304505B true CN115304505B (zh) 2023-06-27

Family

ID=83853908

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110497426.2A Active CN115304505B (zh) 2021-05-08 2021-05-08 烯烃羰基化合成酰胺的方法

Country Status (1)

Country Link
CN (1) CN115304505B (zh)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN87101635A (zh) * 1986-02-28 1988-01-20 国际壳牌研究有限公司 用钯催化剂将不饱合烯烃化合物羰基化的方法
CN88101206A (zh) * 1987-03-11 1988-09-28 国际壳牌研究有限公司 在钯催化剂下烯属不饱和化合物羰基化的方法
US4866177A (en) * 1986-11-24 1989-09-12 Texaco Inc. Process for one-step synthesis of amides
CN1053785A (zh) * 1990-02-05 1991-08-14 国际壳牌研究有限公司 酰胺的制备
CN109293522A (zh) * 2018-11-08 2019-02-01 中国科学院兰州化学物理研究所 一种脂肪酰胺的制备方法
CN112062769A (zh) * 2020-09-03 2020-12-11 中国科学院兰州化学物理研究所 催化氧化氨基烯烃胺羰基化制备五并七元高哌嗪酮衍生物的方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN87101635A (zh) * 1986-02-28 1988-01-20 国际壳牌研究有限公司 用钯催化剂将不饱合烯烃化合物羰基化的方法
US4866177A (en) * 1986-11-24 1989-09-12 Texaco Inc. Process for one-step synthesis of amides
CN88101206A (zh) * 1987-03-11 1988-09-28 国际壳牌研究有限公司 在钯催化剂下烯属不饱和化合物羰基化的方法
CN1053785A (zh) * 1990-02-05 1991-08-14 国际壳牌研究有限公司 酰胺的制备
US5128475A (en) * 1990-02-05 1992-07-07 Shell Oil Company Preparation of amides
CN109293522A (zh) * 2018-11-08 2019-02-01 中国科学院兰州化学物理研究所 一种脂肪酰胺的制备方法
CN112062769A (zh) * 2020-09-03 2020-12-11 中国科学院兰州化学物理研究所 催化氧化氨基烯烃胺羰基化制备五并七元高哌嗪酮衍生物的方法

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Acid-free regioselective aminocarbonylation of alkenes;Huizhen Liu 等;《Chem. Commun.》;第50卷;第7848-7851页 *
Asymmetric Markovnikov Hydroaminocarbonylation of Alkenes Enabled by Palladium-Monodentate Phosphoramidite Catalysis;Ya-Hong Yao 等;《J. Am. Chem. Soc.》;第143卷;第85-91页 *
Palladium-catalyzed highly regioselective hydroaminocarbonylation of aromatic alkenes to branched amides;Jinping Zhu 等;《Org. Biomol. Chem.》;第15卷;第2910-2913页 *
Palladium-Catalyzed Markovnikov Hydroaminocarbonylation of 1,1-Disubstituted and 1,1,2-Trisubstituted Alkenes for Formation of Amides with Quaternary Carbon;Hui-Yi Yang 等;《J. Am. Chem. Soc.》;第143卷;第7298-7305页 *
Selective Palladium-Catalyzed Aminocarbonylation of Olefins to Branched Amides;Jie Liu 等;《Angew. Chem. Int. Ed.》;第55卷;第13544-13548页 *
Selective Palladium-Catalyzed Aminocarbonylation of Olefins with Aromatic Amines and Nitroarenes;Xianjie Fang 等;《Angew. Chem. Int. Ed.》;第52卷;第14089-14093页 *
区域选择性羰基化反应研究进展;黄子俊 等;《分子催化》;第33卷(第6期);第578-591页 *

Also Published As

Publication number Publication date
CN115304505A (zh) 2022-11-08

Similar Documents

Publication Publication Date Title
RU2463290C2 (ru) Получение 3-[(1r,2r)-3-(диметиламино)-1-этил-2-метилпропил]-фенола
US10899681B2 (en) Process for the preparation of deuterated ethanol from D2
AU748360B2 (en) Novel intermediates and processes for the preparation of optically active octanoic acid derivatives
RU2029761C1 (ru) Способ получения 1-(аминометил)циклогексануксусной кислоты
OA10518A (en) Pyrrolidinyl hydroxamic acid compounds and their production process
CN115304505B (zh) 烯烃羰基化合成酰胺的方法
US20140296562A1 (en) Method for producing optically active beta-hydroxy-alpha-aminocarboxylic acid ester
US6187918B1 (en) Catalysts for asymmetric addition of organozinc reagents to aldehydes and method for preparation
IL147668A (en) Process for the preparation of venlafaxin
CZ302992B6 (cs) Zpusob výroby (2R,3R)-N,N-dimethyl-3-(3-hydroxyfenyl)-2-methylpentylaminu (tapentadolu)
JP5434919B2 (ja) カルバメート化合物の製造方法
CN111004264B (zh) 一种n-取代四氢吡啶-3/4-硼酸/酯的制备方法
EP0561758A2 (en) Method of preparing optically active homo-beta-amino acids
JP2006248952A (ja) ケトンの製造法
JP3941651B2 (ja) (メタ)アクリル酸エステル類の製造方法
US6593489B1 (en) Substituted cyclopentenes, their preparation and their use for chiral scaffolds
JP3134786B2 (ja) 2−アザビシクロ[3.3.0]オクタン誘導体とその製造法およびジオールまたはアミノアルコール類の光学分割法
EP0252736A2 (en) Process for preparing fluorine-containing carboxylic acid ester
ファン,ティハンガー Development of Novel Efficient Palladium-Catalyzed Carbonylation Reactions in Combination with Copper Salts
JP2562814B2 (ja) 含フツ素アミド誘導体およびその製造方法
CA2339736A1 (en) Method for producing sorbic acid and sorbic acid esters or derivatives thereof
JP4129495B2 (ja) 2−フルオロシクロプロパンカルボン酸誘導体の製造方法
PL210934B1 (pl) Optycznie czynne pochodne bisoksazoliny, sposób wytwarzania tych związków, substraty i sposób ich wytwarzania
JP2004026790A (ja) ピロリジン誘導体及びその製造方法
JPH07188119A (ja) アミン誘導体およびその製造方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant